Additive Effects of Pravastatin and Valsartan
Information source: Gachon University Gil Medical Center
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension; High Cholesterol
Intervention: pravastatin, valsartan, pravastatin+valsartan (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Gachon University Gil Medical Center Overall contact:
Kwang K Koh, MD,PhD, Phone: 82-32-460-3683, Email: kwangk@gilhospital.com
Summary
The investigators hypothesize that pravastatin combined with valsartan may have additive
effects in hypertensive, hypercholesterolemic patients.
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: flow-mediated dilation
Secondary outcome: insulin resistance
Eligibility
Minimum age: 25 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Hypertension and low-density lipoprotein cholesterol levels >100
Exclusion Criteria:
- Overt liver disease Chronic renal failure Hypothyroidism Myopathy Uncontrolled
diabetes Severe hypertension
Locations and Contacts
Kwang K Koh, MD,PhD, Phone: 82-32-460-3683, Email: kwangk@gilhospital.com
Gil Medical Center, Incheon 405-760, Korea, Republic of; Recruiting
Seung H Han, MD, Phone: 82-32-460-3650, Email: shhan@gilhospital.com
Additional Information
Starting date: November 2009
Last updated: May 9, 2011
|
